FibroGen Inc (NASDAQ:FGEN) has a beta value of 0.81 and has seen 1.13 million shares traded in the last trading session. The company, currently valued at $58.95M, closed the last trade at $0.58 per share which meant it gained $0.03 on the day or 5.50% during that session. The FGEN stock price is -382.76% off its 52-week high price of $2.80 and 68.97% above the 52-week low of $0.18.
The consensus among analysts is that FibroGen Inc (FGEN) is Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.2.
FibroGen Inc (NASDAQ:FGEN) trade information
Sporting 5.50% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the FGEN stock price touched $0.58 or saw a rise of 7.14%. Year-to-date, FibroGen Inc shares have moved 10.48%, while the 5-day performance has seen it change 17.40%. Over the past 30 days, the shares of FibroGen Inc (NASDAQ:FGEN) have changed 0.97%.
Wall Street analysts have a consensus price target for the stock at $28, which means that the shares’ value could jump 97.93% from current levels. The projected low price target is $28.0 while the price target rests at a high of $28.0. In that case, then, we find that the current price level is -4727.59% off the targeted high while a plunge would see the stock gain -4727.59% from current levels.
FibroGen Inc (FGEN) estimates and forecasts
The company’s shares have gained 58.11% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 20.37%.
2 analysts offering their estimates for the company have set an average revenue estimate of 24.91M for the current quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -23.23% over the past 5 years. Earnings growth for 2025 is a modest 72.60% while over the next 5 years, the company’s earnings are expected to increase by 49.34%.
FGEN Dividends
FibroGen Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
FibroGen Inc (NASDAQ:FGEN)’s Major holders
The top two institutional holders are PRIMECAP MANAGEMENT CO/CA/ with over 13.66 million shares worth more than $12.19 million. As of 2024-06-30, PRIMECAP MANAGEMENT CO/CA/ held 13.6785% of shares outstanding.
The other major institutional holder is ARMISTICE CAPITAL, LLC, with the holding of over 8.94 million shares as of 2024-06-30. The firm’s total holdings are worth over $7.97 million and represent 8.9508% of shares outstanding.
